Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
about
Closing the knowledge gap on cardiovascular disease in type 2 diabetes: the EMPA-REG OUTCOME trial and beyondImpact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes.Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes: Pooled Analysis of Phase I-III Clinical Trials.Effect of ertugliflozin on glucose control, body weight, blood pressure and bone density in type 2 diabetes mellitus inadequately controlled on metformin monotherapy (VERTIS MET).Diabetes drugs and the incidence of solid cancers: a survey of the current evidence.Review article: new treatments in non-alcoholic fatty liver disease.Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.The use of sodium-glucose cotransporter 2 inhibitors in patients with type 2 diabetes and hypertension: a focus on African-American populations.Update review of the safety of sodium-glucose cotransporter 2 inhibitors for the treatment of patients with type 2 diabetes mellitus.Cardiovascular safety of therapies for type 2 diabetes.Evaluation of the pharmacokinetics, pharmacodynamics and clinical efficacy of empagliflozin for the treatment of type 2 diabetes.Effects of sodium-glucose co-transporter 2 inhibitors on metabolism: unanswered questions and controversies.Empagliflozin: Role in Treatment Options for Patients with Type 2 Diabetes Mellitus.SGLT2 inhibitor/DPP-4 inhibitor combination therapy - complementary mechanisms of action for management of type 2 diabetes mellitus.Renal Effects of SGLT-2 Inhibitors and Other Anti-diabetic Drugs: Clinical Relevance and Potential Risks.A Case of Septic Shock Due to Serratia marcescens Pyelonephritis and Bacteremia in a Patient Receiving Empagliflozin.Dapagliflozin in patients with type 2 diabetes mellitus: A pooled analysis of safety data from phase IIb/III clinical trials.The Effect of Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibitors on Cardiometabolic Profile; Beyond the Hypoglycaemic Action.Empagliflozin/linagliptin single-pill combination therapy for patients with type 2 diabetes mellitus.Dapagliflozin improves treatment satisfaction in overweight patients with type 2 diabetes mellitus: a patient reported outcome study (PRO study).The impact of SGLT2 inhibitors, compared with insulin, on diabetic bone disease in a mouse model of type 1 diabetes.The heart failure burden of type 2 diabetes mellitus-a review of pathophysiology and interventions.
P2860
Q28075848-CA901E2A-4A92-402E-95EA-1681CC715C79Q33625568-43B6ABC1-6AB4-46D7-AC78-69E7EE7D9EF4Q33845734-9A8D8731-4FF0-46CF-BCEF-54416AA29C7BQ33890770-923F0B7B-E9CE-43C8-98C6-7268CE33F592Q38371417-3E6E76E2-557E-47B8-964C-6633D31BA329Q38651175-D68966B4-8FFA-4B21-A054-1ADA6039015BQ38662765-DEC485CA-CE02-4117-A5DF-26AA921088C4Q38821464-44F69758-8248-4200-A317-89819113D042Q38870752-1E37D1F5-00BA-437B-AEF2-3A44DDC1AEEAQ38906041-A9E36FEB-48E2-4548-82DB-327D35EFD166Q38960547-40BF5C0C-908D-4E0D-850B-62620F6F2643Q39000172-168AC14B-E12B-4A65-872D-5F721FBB8C82Q39000587-738E37DE-6374-42DB-A506-DD0E766A00D1Q39006105-B12E03AB-22BE-4605-A51C-7299DE3B46B0Q39189383-A95AC4B4-BF58-4F19-95CE-74762312FB57Q39290337-F478AD5C-E937-4B72-9639-BF3F81C4B6D1Q40439768-F451B929-62D8-4A6F-B3FE-1A14FE80D2BCQ47918474-5D309F8C-9118-48F2-A08F-E73CFD178048Q51034590-AB877154-E54A-453F-9BC9-7A8DBF389A42Q51072174-F5407939-119F-4F9A-AE20-BC7B7F470FF5Q51744128-FEFC7EAF-BD52-4E91-85A2-E412AF768D9EQ53757094-BB503548-87E7-44A3-8A0C-3E5028F58E29Q55078568-08AE48FB-38AA-4E0B-91FB-128703A40713
P2860
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
@en
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
@nl
type
label
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
@en
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
@nl
prefLabel
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
@en
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes.
@nl
P2093
P1476
Safety and Tolerability of Empagliflozin in Patients with Type 2 Diabetes
@en
P2093
Afshin Salsali
Gabriel Kim
Hans J Woerle
Stefan Hantel
Stefan Kaspers
Uli C Broedl
P304
P356
10.1016/J.CLINTHERA.2016.03.031
P50
P577
2016-04-13T00:00:00Z